Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Volume 9, Number 6—June 2003

Dispatch

Poor Potential Coverage for 7-Valent Pneumococcal Conjugate Vaccine, Malawi

Stephen B. Gordon*Comments to Author , Stonard Kanyanda*, Amanda L. Walsh*, Kristy Goddard*, Mas Chaponda†, Victoria Atkinson†, Wakisa Mulwafu†, Elizabeth M. Molyneux†, Ed E. Zijlstra†, Malcolm E. Molyneux*, and Steve M. Graham*
Author affiliations: *Wellcome Trust Research Laboratories, University of Malawi, Liverpool, U.K.; †University of Malawi College of Medicine, Blantyre, Malawi

Main Article

Figure

The cumulative percentage of all pneumococcal isolates plotted by source (see key). Serogroups covered by the 7-valent vaccine are plotted to the left of the heavy vertical line, and the potential 9-valent coverage is illustrated by the dotted vertical line.

Figure. The cumulative percentage of all pneumococcal isolates plotted by source (see key). Serogroups covered by the 7-valent vaccine are plotted to the left of the heavy vertical line, and the potential 9-valent coverage is illustrated by the dotted vertical line.

Main Article

Page created: December 22, 2010
Page updated: December 22, 2010
Page reviewed: December 22, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external